NRF2 as a ferroptosis gatekeeper in colorectal cancer: implications for therapy
Authors:
- Abdelgawwad El-SehrawyAEAbdelgawwad El-Sehrawy
- Amr Ali MohamedAMAmr Ali Mohamed
- Abdulla A. Al-DulaimiAAAbdulla A. Al-Dulaimi
- Ali G. AlkhathamiAAAli G. Alkhathami
- Renuka Jyothi SRSRenuka Jyothi S
- Rajashree PanigrahiRPRajashree Panigrahi
- Amrita PargaienAPAmrita Pargaien
- Udaybir SinghUSUdaybir Singh
- Ahmed HusseiniAHAhmed Husseini
- 3 July 2025
- journal article
- review article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (12) , 16479-16506
Abstract
Colorectal cancer (CRC) is one of the primary cancer concerns for global health, with high incidence and mortality rates worldwide. The natural history of CRC is a complicated and multistep process characterized by genetic alterations with various biological features, including genomic instability, excessive cell proliferation, angiogenesis, and metastasis. This review focuses on the delicate interaction between ferroptosis, a recently unveiled form of iron-dependent cell death, the nuclear factor erythroid 2-related factor 2 (NRF2), an important transcriptional factor that controls the pharmacology of oxidative stress and cellular metabolism in the context of CRC. NRF2 is critical for regulating the cells’ antioxidant response to compensate for the damage caused by reactive oxygen species and maintain iron homeostasis. By this, NRF2 would function as a negative regulator of ferroptosis, which could be an undesirable process for tumour cells if induced. Certainly, NRF2 activities lower the levels of ROS and manipulate the labile iron pool (LIP). The relationship between NRF2 and ferroptosis is further complicated by the actions of a downstream gene, HO-1, whose expression is regulated by NRF2. NRF2 promotes the transcription of glutathione peroxidase 4 (GPX4) and SLC7A11 (a component of the cystine/glutamate antiporter system Xc⁻). It also regulates iron metabolism by upregulating genes such as ferritin heavy chain (FTH1) and ferroportin (FPN), thus further suppressing ferroptosis. Mounting evidence suggests that targeting the NRF2-ferroptosis axis by Tagitinin C, Lysionotin, Ginsenoside Rh3, Cetuximab, Esculin, Brassinin, and Angelic acid could open up novel therapeutic avenues for treating colorectal cancer, thereby improving CRC patient outcomes and overall survival.Keywords
Funding Information
- King Khalid University (RGP.02/534/44)
This publication has 174 references indexed in Scilit:
- Brassinin from Brassica campestris L. inhibits colorectal cancer by inducing p62/NRF2/GPX4‐regulated ferroptosisAnimal Models and Experimental Medicine, 2025
- Targeting the Labile Iron Pool with Engineered DFO Nanosheets to Inhibit Ferroptosis for Parkinson's Disease TherapyAdvanced Materials, 2024
- Inhibition of CARM1‐Mediated Methylation of ACSL4 Promotes Ferroptosis in Colorectal CancerAdvanced Science, 2023
- FOXA2 Suppression by TRIM36 Exerts Anti‐Tumor Role in Colorectal Cancer Via Inducing NRF2/GPX4‐Regulated FerroptosisAdvanced Science, 2023
- Gambogenic acid inhibits proliferation and ferroptosis by targeting the miR‐1291/FOXA2 and AMPKα/SLC7A11/GPX4 axis in colorectal cancerCell Biology International, 2023
- Inhibition of CDK1 Overcomes Oxaliplatin Resistance by Regulating ACSL4‐mediated Ferroptosis in Colorectal CancerAdvanced Science, 2023
- N‐acetyltransferase 10 promotes colon cancer progression by inhibiting ferroptosis through N4‐acetylation and stabilization of ferroptosis suppressor protein 1 (FSP1) mRNACancer Communications, 2022
- Adipocyte‐Derived Exosomal MTTP Suppresses Ferroptosis and Promotes Chemoresistance in Colorectal CancerAdvanced Science, 2022
- In vitro exosomal transfer of Nrf2 led to the oxaliplatin resistance in human colorectal cancer LS174T cellsCell Biochemistry and Function, 2022
- Evaluation of (S)‐ and (R)‐Misonidazole as GPX Inhibitors: Synthesis, Characterization Including Circular Dichroism and In Vitro Testing on Bovine GPx‐1Archiv der Pharmazie, 2013